Rilvegostomig

雷格苏米单抗

Report date: 2026/05/23 20:00:57

Base Information

Drug NameRilvegostomig
Drug Alias NameAZD-2936
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionT cell immunoglobulin and ITIM domains inhibitorsProgrammed cell death protein 1 blockers
TargetsT cell immunoglobulin and ITIM domainsProgrammed cell death protein 1
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursEndometrial Neoplasms +[19] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[48] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesSamsung Medical CenterBaxter Oncology GmbhAstrazeneca Plc +[8] 
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursEndometrial Neoplasms +[19] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A